Skip to content

DOJ Expands Healthcare Fraud Self-Disclosure Protections for Healthcare Organizations

November 17, 2026

New DOJ–HHS-OIG policy offers healthcare businesses a coordinated path to avoid criminal prosecution and pursue favorable administrative resolutions.

The U.S. Department of Justice (DOJ) and the Department of Health and Human Services Office of Inspector General (HHS-OIG) have established a coordinated framework for healthcare organizations to voluntarily disclose potential criminal fraud. The October 15, 2026, policy allows qualifying healthcare businesses to pursue benefits under the DOJ’s Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP) and HHS-OIG’s Health Care Fraud Self-Disclosure Protocol (SDP) through a single disclosure to the DOJ’s Health Care Fraud Section.

For physicians, healthcare organizations, executives, owners, and investors, the policy creates an opportunity to address potential misconduct before it develops into criminal prosecution. Companies that satisfy the DOJ’s requirements can obtain a declination of criminal prosecution while pursuing favorable administrative resolutions. These protections offer significant benefits, but they do not automatically eliminate financial obligations or individual criminal exposure.

Why This Matters

Healthcare organizations face overlapping criminal, civil, and administrative enforcement risks when investigators uncover improper billing, medically unnecessary services, illegal referral arrangements, or suspected fraud. A single course of conduct can trigger criminal prosecution, False Claims Act litigation, repayment demands, civil monetary penalties, and exclusion from federal healthcare programs. These proceedings can threaten a healthcare business’s financial stability, reputation, and continued operations.

The new policy provides a direct path to address these risks. A qualifying disclosure to the DOJ’s Health Care Fraud Section also provides access to HHS-OIG’s self-disclosure benefits without requiring a duplicate submission. Those benefits include opportunities for faster administrative resolution, lower settlement multipliers, and relief from permissive exclusion without integrity agreement obligations. Companies that satisfy the DOJ’s CEP requirements can also avoid corporate criminal prosecution.

A New Path to Corporate Criminal Protection

The DOJ’s CEP rewards companies that voluntarily disclose misconduct, fully cooperate with investigators, and timely and appropriately remediate violations. When a company satisfies these requirements and no disqualifying aggravating circumstances exist, the DOJ will decline criminal prosecution. Even companies that narrowly miss the declination requirements can qualify for non-prosecution agreements, substantial reductions in criminal fines, and relief from independent compliance monitoring, subject to the policy’s eligibility requirements.

The October 15 policy coordinates these criminal enforcement incentives with HHS-OIG’s administrative disclosure process. A qualifying disclosure involving federal healthcare programs to the DOJ’s Health Care Fraud Section provides access to both agencies’ benefits. HHS-OIG’s updated protocol directs criminal self-disclosures to the DOJ, while OIG continues handling eligible civil monetary penalty matters. A submission solely to HHS-OIG generally does not qualify under the DOJ’s CEP, although prosecutors may consider it when evaluating cooperation and remediation.

A criminal declination does not eliminate every financial or administrative consequence. Companies must satisfy applicable disgorgement, forfeiture, and victim compensation requirements. HHS-OIG’s disclosure process addresses civil monetary penalty liability but does not resolve mandatory exclusion under Section 1128(a) of the Social Security Act. A corporate declination also does not automatically resolve separate False Claims Act claims or other enforcement proceedings. DOJ makes corporate declinations public, creating reputational considerations even when a company avoids prosecution.

Corporate Protection Does Not Extend Automatically to Individuals

The DOJ’s corporate enforcement framework distinguishes between protecting a healthcare business and protecting the individuals who operate it. To obtain full cooperation credit, companies must disclose relevant facts and evidence concerning individuals involved in misconduct, regardless of their positions. Although the policy preserves attorney-client privilege and work-product protections, a healthcare organization can obtain a corporate declination while physicians, executives, owners, and employees remain subject to criminal investigation and prosecution.

The DOJ also maintains a separate, narrowly defined voluntary self-disclosure program for qualifying individuals who provide original information about specified corporate misconduct and assist federal investigators. That program imposes independent eligibility requirements and excludes certain individuals, including chief executive officers, chief financial officers, and organizers or leaders of criminal schemes. A corporate disclosure does not automatically protect those individuals.

These distinctions carry particular significance for physician-owned practices, pharmacies, laboratories, management companies, and other healthcare businesses where owners and executives participate directly in financial and operational decisions. The interests of the business and its leadership may diverge as an investigation develops, making experienced representation essential to protecting both corporate and individual interests.

Impact on Healthcare Organizations and Physicians

The new policy changes how healthcare organizations should evaluate potential misconduct uncovered through internal audits, compliance reviews, employee complaints, and financial examinations. Questions involving medical necessity, billing, kickbacks, referral arrangements, and reimbursement practices can create exposure across multiple enforcement systems. The nature of the conduct, available evidence, government’s existing knowledge, and interests of affected individuals can determine the benefits and consequences of disclosure.

The coordinated framework offers healthcare organizations an opportunity to address misconduct, eliminate duplicate disclosure submissions, and pursue favorable enforcement outcomes. HHS-OIG’s SDP also provides protections concerning identified Medicare and Medicaid overpayments, including suspension of certain reporting and repayment obligations when applicable regulatory requirements are satisfied. These benefits carry important conditions, while the DOJ’s eligibility requirements place particular importance on timely disclosure before an imminent threat of government discovery or investigation.

Experienced healthcare counsel can help physicians and healthcare organizations evaluate disclosure opportunities, protect their interests, and navigate overlapping enforcement proceedings. The objective extends beyond avoiding criminal charges to preserving financial stability, professional relationships, reputation, and the ability to continue serving patients.

Key Takeaway

The DOJ and HHS-OIG have created a coordinated path for healthcare organizations to obtain meaningful benefits through voluntary self-disclosure. Qualifying companies can avoid criminal prosecution or obtain favorable negotiated resolutions while pursuing reduced financial penalties and relief from permissive exclusion. Those protections do not automatically extend to individuals or eliminate every financial and legal consequence.

For physicians, healthcare executives, owners, and investors, the new framework creates an opportunity to protect the businesses they have built. Understanding how the DOJ’s disclosure incentives intersect with individual liability, False Claims Act exposure, and administrative enforcement can make the difference between a manageable resolution and an investigation that threatens the organization’s future.

This publication is intended for general informational purposes only and does not constitute legal advice or a solicitation to provide legal services. The information in this publication is not intended to create, and receipt of it does not constitute, a lawyer-client relationship. Readers should not act upon this information without seeking professional legal counsel. The views and opinions expressed herein represent those of the individual author only and are not necessarily the views of Clark Hill PLC. Although we attempt to ensure that postings on our website are complete, accurate, and up to date, we assume no responsibility for their completeness, accuracy, or timeliness.

Subscribe for the latest

Subscribe